Christina A Eichstaedt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1095397/publications.pdf

Version: 2024-02-01

44 papers	2,778 citations	279798 23 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	4657 citing authors

#	Article	IF	Citations
1	The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review. Heart Failure Reviews, 2023, 28, 193-206.	3.9	3
2	Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. Respiratory Research, 2022, 23, 74.	3.6	18
3	Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?. Genes, 2022, 13, 759.	2.4	2
4	Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. Science Translational Medicine, 2022, 14, .	12.4	15
5	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. European Heart Journal, 2021, 42, 2284-2295.	2.2	51
6	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
7	The Experience, Prerequisites, and the Barriers in Organizing a Specialized Rehabilitation Program for Patients with Pulmonary Hypertension. Respiration, 2021, 100, 1-9.	2.6	0
8	Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension. Respiratory Research, 2021, 22, 288.	3.6	6
9	BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients. Genes, 2020, 11, 1168.	2.4	3
10	Supervised Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension as Early Follow-Up Treatment after Pulmonary Endarterectomy: A Prospective Cohort Study. Respiration, 2020, 99, 577-588.	2.6	18
11	Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertensionâ€"A Genetic Study. International Journal of Molecular Sciences, 2020, 21, 3339.	4.1	13
12	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
13	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nature Communications, 2020, 11, 1185.	12.8	52
14	Genetic Predisposition to High-Altitude Pulmonary Edema. High Altitude Medicine and Biology, 2020, 21, 28-36.	0.9	21
15	Genetics of pulmonary hypertension and high-altitude pulmonary edema. Journal of Applied Physiology, 2020, 128, 1432-1438.	2.5	15
16	Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. Respiratory Research, 2020, 21, 127.	3.6	14
17	Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis. Diagnostics, 2020, 10, 1110.	2.6	6
18	Multicentre trials on specialised exercise training and rehabilitation are useful in patients with pulmonary hypertension. European Respiratory Journal, 2019, 54, 1901631.	6.7	2

#	Article	IF	Citations
19	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Research and Therapy, 2019, 21, 217.	3.5	34
20	Mutually reinforcing effects of genetic variants and interferonâ€î² 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients. Pulmonary Circulation, 2019, 9, 1-6.	1.7	9
21	The role of rehabilitation in patients with pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2019, 25, 398-404.	2.6	5
22	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	6.7	110
23	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respiratory Research, 2018, 19, 258.	3.6	39
24	Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 4-10.	1.7	26
25	Exercise Training and Rehabilitation in Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 425-430.	2.1	21
26	Circulating MicroRNA Markers for Pulmonary Hypertension in Supervised Exercise Intervention and Nightly Oxygen Intervention. Frontiers in Physiology, 2018, 9, 955.	2.8	14
27	First identification of KrÃ¼ppel-like factor 2 mutation in heritable pulmonary arterial hypertension. Clinical Science, 2017, 131, 689-698.	4.3	38
28	Evidence of Early-Stage Selection on EPAS1 and GPR126 Genes in Andean High Altitude Populations. Scientific Reports, 2017, 7, 13042.	3.3	29
29	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.	6.7	489
30	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	10.7	307
31	Identification of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. Clinical Science, 2016, 130, 2043-2052.	4.3	25
32	EIF2AK4 mutation as â€œsecond hitâ€•in hereditary pulmonary arterial hypertension. Respiratory Research, 2016, 17, 141.	3.6	33
33	Genomic analyses inform on migration events during the peopling of Eurasia. Nature, 2016, 538, 238-242.	27.8	360
34	Selective sweep on human amylase genes postdates the split with Neanderthals. Scientific Reports, 2016, 6, 37198.	3.3	67
35	Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Pharmacological Research, 2016, 114, 103-109.	7.1	33
36	Genetic and phenotypic differentiation of an Andean intermediate altitude population. Physiological Reports, 2015, 3, e12376.	1.7	18

#	Article	IF	Citations
37	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127.	2.5	185
38	Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2015, 195, 19-26.	1.7	46
39	A recent bottleneck of Y chromosome diversity coincides with a global change in culture. Genome Research, 2015, 25, 459-466.	5.5	348
40	Positive selection of AS3MT to arsenic water in Andean populations. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 780, 97-102.	1.0	32
41	Analysis of fullâ€length mitochondrial DNA Dâ€loop sequences from Macaca fascicularis of different geographical origin reveals novel haplotypes. Journal of Medical Primatology, 2015, 44, 125-136.	0.6	6
42	Mutation in BMPR2 Promoter: A â€˜Second Hitâ€™ for Manifestation of Pulmonary Arterial Hypertension?. PLoS ONE, 2015, 10, e0133042.	2.5	26
43	Genome-Wide Analysis of Cold Adaptation in Indigenous Siberian Populations. PLoS ONE, 2014, 9, e98076.	2.5	128
44	The Andean Adaptive Toolkit to Counteract High Altitude Maladaptation: Genome-Wide and Phenotypic Analysis of the Collas. PLoS ONE, 2014, 9, e93314.	2.5	55